0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Glucosylceramidase

Glucosylceramidase

Brief Information

Name:Glucosylceramidase
Target Synonym:Glucosylceramidase
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
GLE-H52H3 Human Human Glucosylceramidase Protein, His Tag
GLE-H52H3-structure
GLE-H52H3-sds
ACRO Quality

Synonym Name

Glucosylceramidase,GBA,Acid beta-glucosidase,Alglucerase,beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,EC 3.2.1.45,GBA,GBA1,GC,GCB,GLUC,glucosidase, beta, acid,glucosidase, beta,acid (includes glucosylceramidase),Glucosylceramidase,I

Background

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides,it participates in the PKC-activated salvage pathway of ceramide formation and plays a role in cholesterol metabolism. It may either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency. Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Currently, enzyme replacement therapy is used to treat patients with the disease.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GT-02287 GT-02287 Phase 1 Clinical Gain Therapeutics Inc Parkinson Disease Details
VQ-101 VQ-101 Phase 1 Clinical Vanqua Bio Inc Parkinson Disease Details
GT-02287 GT-02287 Phase 1 Clinical Gain Therapeutics Inc Parkinson Disease Details
VQ-101 VQ-101 Phase 1 Clinical Vanqua Bio Inc Parkinson Disease Details

This web search service is supported by Google Inc.

totop

Nachricht schicken